Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-10-23 6:09 pm Purchase | 13G | BRIGHT MINDS BIOSCIENCES INC. DRUG | Logos Global Management LP | 100,000 2.2% | 100,000 (New Position) | View |
2024-08-27 5:22 pm Purchase | 13G | CYBIN INC CYBN | Logos Global Management LP | 40,000,000 5.3% | 40,000,000 (New Position) | View |
2024-08-13 6:53 pm Purchase | 13D | DESIGN THERAPEUTICS INC DSGN | Logos Global Management LP | 4,232,627 7.5% | 1,420,126 (+50.49%) | View |
2024-06-06 6:49 pm Sale | 13D | OLEMA PHARMACEUTICALS INC OLMA | Logos Global Management LP | 3,248,818 5.8% | -1,018,130 (-23.86%) | View |
2024-04-01 6:34 pm Purchase | 13G | NEXTCURE INC NXTC | Logos Global Management LP | 2,000,460 7.2% | 2,000,460 (New Position) | View |
2024-02-22 3:47 pm Purchase | 13G | ADVERUM BIOTECHNOLOGIES INC CO ADVM | Logos Global Management LP | 15,000,000 7.2% | 15,000,000 (New Position) | View |
2024-02-14 4:01 pm Sale | 13G | Allakos Inc. ALLK | Logos Global Management LP | 2,900,000 3.3% | -2,386,666 (-45.15%) | View |
2024-02-14 3:51 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | Logos Global Management LP | 150,000 0.4% | 150,000 (New Position) | View |
2024-02-13 7:31 pm Sale | 13G | IDEAYA Biosciences Inc. IDYA | Logos Global Management LP | 1,800,000 2.8% | -2,100,000 (-53.85%) | View |
2024-02-13 7:23 pm Purchase | 13G | Annexon Inc. ANNX | Logos Global Management LP | 6,944,444 8.3% | 3,844,444 (+124.01%) | View |
2024-01-22 4:57 pm Purchase | 13G | ELEVATION ONCOLOGY INC ELEV | Logos Global Management LP | 3,650,000 8.6% | 3,650,000 (New Position) | View |
2024-01-22 4:27 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Logos Global Management LP | 3,469,927 9.9% | 3,469,927 (New Position) | View |
2024-01-02 12:21 pm Purchase | 13G | aTYR PHARMA INC ATYR | Logos Global Management LP | 5,800,000 9.9% | 5,800,000 (New Position) | View |
2023-11-27 5:39 pm Purchase | 13D | OLEMA PHARMACEUTICALS INC OLMA | Logos Global Management LP | 4,266,948 7.8% | 508,130 (+13.52%) | View |
2023-07-18 4:01 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | Logos Global Management LP | 6,350,000 8.1% | 6,350,000 (New Position) | View |
2023-06-22 1:25 pm Purchase | 13G | Annexon Inc. ANNX | Logos Global Management LP | 3,100,000 5.8% | 3,100,000 (New Position) | View |
2023-02-14 4:23 pm Sale | 13G | Allakos Inc. ALLK | Logos Global Management LP | 5,286,666 6.2% | -650,000 (-10.95%) | View |
2023-02-14 4:14 pm Purchase | 13G | IDEAYA Biosciences Inc. IDYA | Logos Global Management LP | 3,900,000 8.1% | 3,900,000 (New Position) | View |
2023-02-14 4:07 pm Sale | 13G | BICYCLE THERAPEUTICS PLC BCYC | Logos Global Management LP | 1,435,000 4.8% | -115,000 (-7.42%) | View |
2023-02-14 3:53 pm Sale | 13G | Dyne Therapeutics Inc. DYN | Logos Global Management LP | 2,150,000 4.1% | -804,392 (-27.23%) | View |